A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Subscribe To Our Newsletter & Stay Updated
